MedImmune COO retiring
MedImmune Chief Operating Officer Melvin Booth will retire around end of the year, the company tells earnings call Oct. 23. "We do not have any immediate plans to fill the COO position," CEO David Mott said. Booth joined MedImmune in 1998 from Human Genome Sciences (1"The Pink Sheet" Sept. 21, 1998, In Brief)...
You may also be interested in...
Former Syntex Labs President Melvin Booth appointed Medimmune president and COO reporting to Chairman and CEO Wayne Hockmeyer, PhD. Booth joins Medimmune from Human Genome Sciences, where he was president
India has approved a $46m project by giving the green light to 16 drug production applications under the Production Linked Incentive scheme. The government has ordered the setting up and commercial production of the 16 projects to commence immediately.
Off-label use of cancer drugs in China is legal and even common in certain cases. But a line has been crossed in cases of active promotion and even conflicts of interest for some high-priced products and unproven cell therapies, unveiled by a Chinese physician whistleblower, regulatory observers say.